Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Patrizia Carpinelli"'
Autor:
Dalila Boi, Fani Souvalidou, Davide Capelli, Federica Polverino, Grazia Marini, Roberta Montanari, Giorgio Pochetti, Angela Tramonti, Roberto Contestabile, Daniela Trisciuoglio, Patrizia Carpinelli, Camilla Ascanelli, Catherine Lindon, Alessandro De Leo, Michele Saviano, Roberto Di Santo, Roberta Costi, Giulia Guarguaglini, Alessandro Paiardini
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 23, p 13122 (2021)
Neuroblastoma is a severe childhood disease, accounting for ~10% of all infant cancers. The amplification of the MYCN gene, coding for the N-Myc transcription factor, is an essential marker correlated with tumor progression and poor prognosis. In neu
Externí odkaz:
https://doaj.org/article/95ae0f8e2a4a42f28065143f67055798
Autor:
Alessio Polacchini, Clara Albani, Gabriele Baj, Andrea Colliva, Patrizia Carpinelli, Enrico Tongiorgi
Publikováno v:
Biology Open, Vol 5, Iss 7, Pp 899-907 (2016)
Drug-resistance to chemotherapics in aggressive neuroblastoma (NB) is characterized by enhanced cell survival mediated by TrkB and its ligand, brain-derived neurotrophic factor (BDNF); thus reduction in BDNF levels represent a promising strategy to o
Externí odkaz:
https://doaj.org/article/c4a54c6ce7a24e619747f4c93e619788
Autor:
Gautam Borthakur, Herve Dombret, Philippe Schafhausen, Tim Henrik Brummendorf, Nicolas Boissel, Elias Jabbour, Mariangela Mariani, Laura Capolongo, Patrizia Carpinelli, Cristina Davite, Hagop Kantarjian, Jorge E. Cortes
Publikováno v:
Haematologica, Vol 100, Iss 7 (2015)
Danusertib is a pan-aurora kinase inhibitor with potent activity against Abl kinase including the gatekeeper T315I mutant. A phase 1 dose escalation study of danusertib was conducted in patients with accelerated or blastic phase chronic myeloid leuke
Externí odkaz:
https://doaj.org/article/3dea874cb3f14cd8a5ff44465a306c23
Autor:
Jürgen Moll, Daniele Fancelli, Enrico Pesenti, Dario Ballinari, Aurelio Marsiglio, Veronica Patton, Cristina Alli, Chiara Soncini, Claudio Arrigoni, Paola Zugnoni, Paola Storici, Luisa Rusconi, Paola Vianello, Maurizio Rocchetti, Gemma Texido, Anna Degrassi, Valter Croci, Laura Gianellini, Paolo Cappella, Maria Laura Giorgini, Roberta Ceruti, Patrizia Carpinelli
Supplementary Fig. S1 from PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ad37abd8e1e506016be814b1b51c632
https://doi.org/10.1158/1535-7163.22483142.v1
https://doi.org/10.1158/1535-7163.22483142.v1
Autor:
Jürgen Moll, Daniele Fancelli, Enrico Pesenti, Dario Ballinari, Aurelio Marsiglio, Veronica Patton, Cristina Alli, Chiara Soncini, Claudio Arrigoni, Paola Zugnoni, Paola Storici, Luisa Rusconi, Paola Vianello, Maurizio Rocchetti, Gemma Texido, Anna Degrassi, Valter Croci, Laura Gianellini, Paolo Cappella, Maria Laura Giorgini, Roberta Ceruti, Patrizia Carpinelli
Supplementary Table S1 from PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c070b33c5aefdf25ed1f037d109f678
https://doi.org/10.1158/1535-7163.22483139.v1
https://doi.org/10.1158/1535-7163.22483139.v1
Autor:
Jürgen Moll, Daniele Fancelli, Enrico Pesenti, Dario Ballinari, Aurelio Marsiglio, Veronica Patton, Cristina Alli, Chiara Soncini, Claudio Arrigoni, Paola Zugnoni, Paola Storici, Luisa Rusconi, Paola Vianello, Maurizio Rocchetti, Gemma Texido, Anna Degrassi, Valter Croci, Laura Gianellini, Paolo Cappella, Maria Laura Giorgini, Roberta Ceruti, Patrizia Carpinelli
PHA-739358 is a small-molecule 3-aminopyrazole derivative with strong activity against Aurora kinases and cross-reactivities with some receptor tyrosine kinases relevant for cancer. PHA-739358 inhibits all Aurora kinase family members and shows a dom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebb0bde1377ecffa21e6fcbd2a5240d3
https://doi.org/10.1158/1535-7163.c.6531083.v1
https://doi.org/10.1158/1535-7163.c.6531083.v1
Autor:
Jürgen Moll, Antonella Isacchi, Alexander D. Cameron, Patrizia Carpinelli, Daniele Fancelli, Luisa Rusconi, Rosita Lupi, Riccardo Colombo, Pamela Rosettani, Chiara Soncini, Elena Casale, Michele Modugno
Mutations in the kinase domain of Bcr-Abl are the most common cause of resistance to therapy with imatinib in patients with chronic myelogenous leukemia (CML). Second-generation Bcr-Abl inhibitors are able to overcome most imatinib-resistant mutants,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd319d534851153a0e0e679178e5bf0b
https://doi.org/10.1158/0008-5472.c.6496034
https://doi.org/10.1158/0008-5472.c.6496034
Autor:
Jürgen Moll, Antonella Isacchi, Alexander D. Cameron, Patrizia Carpinelli, Daniele Fancelli, Luisa Rusconi, Rosita Lupi, Riccardo Colombo, Pamela Rosettani, Chiara Soncini, Elena Casale, Michele Modugno
Supplementary Table 1 from Crystal Structure of the T315I Abl Mutant in Complex with the Aurora Kinases Inhibitor PHA-739358
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ec67113b12c717c73d8943be728656c
https://doi.org/10.1158/0008-5472.22368614.v1
https://doi.org/10.1158/0008-5472.22368614.v1
Autor:
Alessandro Di Sanzo, Claudia Di Giulio, Arturo Galvani, Glen J. Weiss, Francesco Fiorentini, Barbara Valsasina, Daniel D. Von Hoff, Gayle S. Jameson, Ramesh K. Ramanathan, Cristina Davite, Rachele Alzani, Antonella Isacchi, Patrizia Carpinelli
Publikováno v:
Investigational new drugs. 36(1)
Background Pharmacological inhibition of polo-like kinase 1 (PLK1) represents a new approach for the treatment of solid tumors. This study was aimed at determining the first cycle dose-limiting toxicities (DLTs) and related maximum tolerated dose (MT
Autor:
Elena Casale, Patrizia Carpinelli, Claudia Perrera, Ulisse Cucchi, Giulia Canevari, Barbara Forte, Eduard R. Felder, J.A. Bertrand, Stefania Re Depaolini
Publikováno v:
Biochemistry. 52:6380-6387
Maternal embryonic leucine zipper kinase (MELK) is upregulated in several types of tumor, including breast, prostate, and brain tumors. Its expression is generally associated with cell survival, cell proliferation, and resistance to apoptosis. Theref